Clinical Trial Supply (CTS) is the backbone of successful clinical research, ensuring tentative products reach the right patients, at the right sites, and at the right time. From demand forecasting and packaging to cold chain logistics and global distribution, CTS drives efficiency, compliance, and patient safety throughout every phase of a clinical trial. World BI is pleased to present the Clinical Trial Supply Forum, a distinguished platform that brings together industry leaders, experts, and decision-makers to discuss emerging trends, address critical challenges, and exchange strategic insights shaping the future of clinical trial supply.

Introduction

The global clinical research landscape has become increasingly interconnected, with pharmaceutical companies relying on international manufacturing networks, specialized suppliers, and global logistics providers to ensure the uninterrupted supply of Investigational Medicinal Products (IMPs). However, in 2027, evolving trade policies and rising tariffs have emerged as significant challenges for the clinical trial supply industry. As governments implement new import duties, revise trade agreements, and strengthen domestic manufacturing initiatives, sponsors and contract research organizations (CROs) are facing growing uncertainty in sourcing, transporting, and distributing IMPs across borders.

01Understanding the Impact of Tariffs on Clinical Trial Supply

Tariffs are taxes imposed on imported goods, often introduced to protect domestic industries or respond to changing international trade relationships. While these measures primarily target commercial trade, they also affect the movement of pharmaceutical products, raw materials, packaging components, laboratory equipment, and clinical trial supplies. For sponsors conducting multinational clinical trials, increased import duties can significantly raise procurement costs and complicate cross-border distribution. Investigational products frequently cross multiple international borders during manufacturing, packaging, labeling, storage, and final distribution to clinical sites.

02Why IMP Sourcing Is Becoming More Complex

Investigational Medicinal Products require strict quality controls, regulatory documentation, temperature-controlled transportation, and timely delivery to trial sites. Tariff-related disruptions amplify these challenges in several ways. Manufacturers may experience increased production costs due to higher prices for imported active pharmaceutical ingredients (APIs), packaging materials, or specialized manufacturing equipment. Logistics providers face additional customs inspections, documentation requirements, and border delays that can extend shipment timelines. For temperature-sensitive biologics, cell and gene therapies, vaccines, and personalized medicines, even minor shipping delays may compromise product integrity.

03Rising Costs across the Clinical Supply Chain

The financial implications of trade tariffs extend well beyond import taxes. Clinical trial sponsors are experiencing increased expenses across multiple stages of the supply chain, including:

  • Procurement of pharmaceutical ingredients
  • Manufacturing and secondary packaging
  • Labeling and country-specific compliance
  • Cold chain transportation
  • Customs brokerage and regulatory documentation
  • Warehousing and inventory management
  • Global distribution and site delivery

04Supply Chain Resilience Has Become a Strategic Priority

Rather than relying on a single supplier or manufacturing region, many pharmaceutical companies are adopting diversified sourcing strategies. Multi-regional supplier networks reduce dependency on countries affected by new tariffs while improving business continuity during geopolitical disruptions. Organizations are also investing in regional manufacturing facilities and localized packaging operations. Producing investigational products closer to clinical trial sites reduces transportation costs, shortens delivery timelines, and minimizes exposure to changing trade policies.

05Digital Technologies are Supporting Smarter Decision-Making

Digital transformation is helping organizations respond more effectively to tariff-related uncertainty. Artificial intelligence, predictive analytics, and advanced supply chain management platforms provide greater visibility into inventory levels, transportation risks, customs requirements, and supplier performance. Real-time monitoring allows clinical supply teams to identify potential disruptions before they impact patients.

06Regulatory Compliance Remains Critical

Trade policy changes frequently introduce new customs procedures, import documentation requirements, and regulatory obligations. Clinical supply teams must ensure every shipment complies with country-specific regulations while maintaining Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) standards. Close collaboration between regulatory affairs, quality assurance, and supply chain professionals is essential to avoid shipment delays, customs holds, or product shortages. Early planning and proactive communication with regulatory authorities can significantly reduce operational risks associated with international distribution.

07Strategies for Managing Tariff-Related Disruptions

Forward-looking organizations are implementing several practical strategies to strengthen their clinical trial supply operations:

  • Diversifying supplier and manufacturing locations to reduce geographic dependency.
  • Establishing regional distribution centers closer to clinical trial sites.
  • Increasing inventory visibility through digital supply chain platforms.
  • Strengthening relationships with experienced logistics and customs partners.
  • Conducting regular risk assessments for global sourcing activities.
  • Developing contingency plans for high-risk trade routes.

08The Future of Clinical Trial Supply in 2027

The clinical trial supply industry is entering a period of significant transformation. While tariffs present immediate challenges, they are also encouraging organizations to build more resilient, flexible, and technology-driven supply networks.

Future clinical supply strategies will increasingly emphasize regional manufacturing, digital supply chain visibility, supplier diversification, sustainable logistics, and proactive risk management. Artificial intelligence, automation, and advanced analytics will play an even greater role in supporting strategic sourcing decisions and improving operational efficiency.

09Conclusion

Trade policies and tariffs are reshaping the global clinical trial supply landscape in 2027. Their impact extends beyond increased costs, influencing every stage of Investigational Medicinal Product sourcing from procurement and manufacturing to distribution and regulatory compliance. As international clinical research becomes more complex, sponsors must adopt agile sourcing strategies, strengthen supplier networks, and leverage digital technologies to mitigate risk. Success in today's environment depends on more than simply moving products across borders. It requires resilient planning, strategic partnerships, regulatory excellence, and continuous innovation.

10Clinical Trial Supply Forum

As clinical trial supply chains continue to grow in complexity, collaboration, innovation, and the exchange of industry expertise have become more important than ever. In response to these evolving challenges, World BI is proud to present the Clinical Trial Supply Forum once again, bringing together global leaders, industry experts, and decision-makers to explore emerging trends, share best practices, and discuss innovative strategies shaping the future of clinical trial supply management.